{
    "clinical_study": {
        "@rank": "13444", 
        "brief_summary": {
            "textblock": "This aim of the study is to investigate the prognostic usefulness of AdreView\u2122 imaging to\n      identify those subjects with New York Heart Association (NYHA) Class II or III HF who will\n      die during 60 months of follow-up from the date of administration of AdreView\u2122 in prior\n      studies MBG311, MBG312, or MBG312C (hereafter included in MBG312)."
        }, 
        "brief_title": "Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView\u2122 Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure (HF)", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject was a HF subject who had signed informed consent for MBG311 or MBG312.\n\n          -  The subject was administered AdreView\u2122 in MBG311 or MBG312.\n\n          -  The subject completed the late planar imaging assessments (at a minimum) required by\n             the protocols for MBG311 and MBG312, and those images were read and judged diagnostic\n             by at least 2 blinded readers.\n\n          -  In addition, all subjects must meet 1 of the following 3 inclusion criteria.\n\n          -  If the subject can be located, he/she provides informed consent to allow the\n             investigator access to medical records and/or gives permission for the investigator\n             to speak to treating physicians.\n\n          -  If the subject can be located and he/she declines to provide informed consent, the\n             IRB/EC provides a waiver of consent to allow the investigator to record that the\n             subject is alive.\n\n          -  If the subject cannot be located, the IRB/EC provides a waiver of consent to allow\n             the investigator to access available medical records for care provided subsequent to\n             last date of subject participation in MBG311, MBG312, and/or MBG313 and/or to allow\n             collection of data from publicly available sources.\n\n        Exclusion Criteria:\n\n          -  The subject withdrew or was withdrawn from MBG311 or MBG312 because of a protocol\n             violation.\n\n          -  The subject underwent heart transplantation during MBG311, MBG312, or MBG313.\n\n          -  The subject was recorded to have died during MBG311, MBG312, or MBG313.\n\n          -  The subject voluntarily withdrew from MBG311, MBG312, or MBG313, and the IRB/EC has\n             not provided a waiver to allow recording of subject survival status in such an\n             instance.\n\n          -  The subject cannot be located, cannot be contacted, and no information can be found\n             to establish survival status beyond the date of last contact in MBG311, MBG312, or\n             MBG313, including information available as a result of an IRB/EC-approved waiver."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Heart Failure patients (NYHA Class II or III) with left ventricular ejection fraction \u226435%\n        at time of enrolment in MBG311 or MBG312."
            }
        }, 
        "enrollment": {
            "#text": "860", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127307", 
            "org_study_id": "GE-122-016"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Myocardial sympathetic innervation", 
            "Heart failure (HF)", 
            "Nuclear imaging", 
            "Radiopharmaceutical"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "Chelsa.MacMeekin@ge.com", 
                "last_name": "Chelsa MacMeekin", 
                "phone": "609-514-6325"
            }, 
            "contact_backup": {
                "email": "Jay.Chahal@ge.com", 
                "last_name": "Jay Chahal", 
                "phone": "011-44-1494-543915"
            }, 
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "GE Healthcare"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView\u2122 Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.", 
        "overall_contact": {
            "email": "Chelsa.MacMeekin@ge.com", 
            "last_name": "Chelsa MacMeekin", 
            "phone": "609-514-6325"
        }, 
        "overall_contact_backup": {
            "email": "Jay.Chahal@ge.com", 
            "last_name": "Jay Chahal", 
            "phone": "011-44-1494-543915"
        }, 
        "overall_official": {
            "affiliation": "GE Healthcare", 
            "last_name": "Arnold Jacobson, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Denmark: Danish Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Demonstrate the prognostic usefulness of assessment of myocardial sympathetic innervation, as reflected by the heart to mediastinum (H/M) ratio on planar AdreView\u2122 (123I mIBG)  imaging dichotomized as either <1.60 or \u22651.60, for identifying heart failure (HF) subjects at lower risk of death during 60 months of follow-up.", 
            "measure": "Demonstrate the prognostic usefulness of assessment of myocardial sympathetic innervation", 
            "safety_issue": "No", 
            "time_frame": "AdreView\u2122 image scans were previously acquired according to AdreView\u2122 studies, MBG311 or MBG312.  Estimated time to collect new information in this study is 6 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Demonstrate that for heart failure (HF) subjects with moderate and severe abnormal myocardia sympathetic innervation, as measured by the numerical H/M ratio on planar AdreView\u2122 imaging dichotomized as either 1.20-1.59 or <1.20, both groups are at higher risk of death during 60 months of follow-up than HF subjects with H/M\u22651.60.", 
            "measure": "Demonstrate that for heart failure (HF) subjects with moderate and severe abnormal myocardia sympathetic innervation", 
            "safety_issue": "No", 
            "time_frame": "AdreView\u2122 image scans were previously acquired according to AdreView\u2122 studies, MBG311 or MBG312.  Estimated time to collect new information in this study is 6 months."
        }, 
        "source": "GE Healthcare", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "H2O Clinical LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Quintiles LTD", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}